Prognostic significance of p53 and p21(waf1/cip1) immunoreactivity in epithelial cancers of the ovary

Gynecologic Oncology

Volumn 75, Issue 3, 1999, Pages 413-418

  Werness, Bruce A ^a   Freedman, Andrew N ^a   Piver, M Steven ^a   Romero Gutierrez, Maritza ^a   Petrow, Ed ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Ovarian neoplasms; P21; P53; Prognosis; Waf1

Indexed keywords

PROTEIN P21; PROTEIN P53;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME;

EID: 0032763270     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5601     Document Type: Article

References (40)

1. Landis S H, Murray T, Bolden S, Wingo P A. Cancer statistics, 1999. CA. Cancer J Clin. 49:1999;8-41.
2. Renninson J, Baker B W, McGown A T, Murphy D, Norton J D, Fox B W, Crowther D. Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: Correlation with histopathology and clinical features. Br J Cancer. 69:1994;609-612.
3. Kohler M F, Kerns B J, Humphrey P A, Marks J R, Bast R C Jr., Berchuck A. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol. 81:1993;643-650.
4. Henriksen R, Strang P, Wilander E, Backstrom T, Tribukait B, Oberg K. p53 expression in epithelial ovarian neoplasms: Relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol. 53:1994;301-306.
5. Niwa K, Itoh M, Murase T, Morishita S, Itoh N, Mori H, Tamaya T. Alteration of p53 gene in ovarian carcinoma: Clinicopathological correlation and prognostic significance. Br J Cancer. 70:1994;1191-1197.
6. Kupryjanczyk J, Thor A D, Beauchamp R, Merritt V, Edgerton S M, Bell D A, Yandell D W. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA. 90:1993;4961-4965.
7. Kanbour-Shakir A, Kounelis S, Papadaki H, Raptis S, Edwards R P, Kelley J LI, Price F V, Bakker A, Swalsky P A, Przygodzki R M, Finkelstein S D. Relationship of p53 genotype to second-look recurrence and survival in ovarian epithelial malignancy. Mol Diagnosis. 1:1996;121-129.
8. Rohlke P, Milde-Langosch K, Weyland C, Pichlmeier U, Jonat W, Loning T. p53 is a persistent and predictive marker in advanced ovarian carcinomas: Multivariate analysis including comparison with Ki67 immunoreactivity. J Cancer Res Clin Oncol. 123:1997;496-501.
9. Levesque M A, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, Diamandis E P. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer. 75:1995;1327-1338.
10. Sheridan E, Silcocks P, Smith J, Hancock B W, Goyns M H. p53 mutation in a series of epithelial ovarian cancers from the U.K., and its prognostic significance. Eur J Cancer. 30A:1994;1701-1704.
11. Marks J R, Davidoff A M, Kerns B J, Humphrey P A, Pence J C, Dodge R K, Clarke-Pearson D L, Iglehart J D, Bast R C Jr, Berchuck A. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res. 51:1991;2979-2984.
12. Dong Y, Walsh M D, McGuckin M A, Cummings M C, Gabrielli B G, Wright G R, Hurst T, Khoo S K, Parsons P G. Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer. Int J Cancer. 74:1997;407-415.
13. Klemi P J, Pylkkanen L, Kiilholma P, Kurvinen K, Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer. 76:1995;1201-1208.
14. Diebold J, Suchy B, Baretton G B, Blasenbreu S, Meier W, Schmidt M, Rabes H, Lohrs U. DNA ploidy and MYC DNA amplification in ovarian carcinomas. Correlation with p53 and bcl-2 expression, proliferative activity and prognosis. Virchows Arch. 429:1996;221-227.
15. Eltabbakh G H, Belinson J L, Kennedy A W, Biscotti C V, Casey G, Tubbs R R, Blumenson L E. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer. 80:1997;892-898.
16. Hartmann L C, Podratz K C, Keeney G L, Kamel N A, Edmonson J H, Grill J P, Su J Q, Katzmann J A, Roche P C. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol. 12:1994;64-69.
17. Skomedal H, Kristensen G B, Abeler V M, Borresen-Dale A L, Trope C, Holm R. TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas. J Pathol. 181:1997;158-165.
18. Waldman T, Kinzler K W, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55:1995;5187-5190.
19. el-Deiry W S, Tokino T, Velculescu V E, Levy D B, Parsons R, Trent J M, Mercer W E, Kinzler K W, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
20. el-Deiry W S, Harper J W, O'Connor P M, Velculescu V E, Canman C E, Jackman J, Pietenpol J A, Burrell M, Hill D E, Wang Y, Wiman K G, Mercer W E, Kastan M B, Kohn K W, Elledge S J, Kinzler K W, Vogelstein B. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54:1994;1169-1174.
21. Datto M B, Li Y, Panus J F, Howe D J, Xiong Y, Wang X F. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA. 92:1995;5545-5549.
22. Johnson M, Dimitrov D, Vojta P J, Barrett J C, Pereira-Smith O M, Smith J R. Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 RNA in human cells. Mol Carcinogenesis. 11:1994;59-64.
23. Michieli P, Chedid M, Lin D, Pierce J H, Mercer W E, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 54:1994;3391-3395.
24. DiGiuseppe J A, Redston M S, Yeo C J, Kern S E, Hruban R H. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol. 147:1995;884-888.
25. Jung J M, Bruner J M, Ruan S, Langford L A, Kyritsis A P, Kobayashi T, Zhang W. Increased levels of p21 WAF1/Cip1 in human brain tumors. Oncogene. 11:1995;2021-2028.
26. Werness B A, Wang H Q, Chance J, Goldstein D J. p53-independent expression of p21waf1/cip1 in preinvasive and invasive squamous neoplasms of the uterine cervix. Mod Pathol. 10:1997;578-584.
27. El-Deiry W AS, Tokino T, Waldman T, Oliner J D, Velculescu V E, Burrell M, Hill D E, Healy E, Rees J L, Hamilton S R, Kinzler K W, Vogelstein B. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res. 55:1995;2910-2919.
28. Ozcelik H, Mousses S, Andrulis I L. Low levels of expression of an inhibitor of cyclin-dependent kinases (cip1/waf1) in primary breast carcinomas with p53 mutations. Clin Cancer Res. 1:1995;907-912.
29. Zedenius J, Larsson C, Wallin G, Backdahl M, Aspenblad U, Hoog A, Auer G. Alterations of p53 and expression of waf1/p21 in human thyroid tumors. Thyroid. 6:1996;1-9.
30. Am J Obstet Gynecol. 156:1987;263.
31. Hakes T B. Prognostic factors in ovarian cancer. Markman M, Hoskins W J. Cancer of the Ovary. 1993;115-131 Raven Press, New York.
32. Ozols R F, Garvin A J, Costa J, Simon R M, Young R C. Histologic grade in advanced ovarian cancer. Cancer Treatment Rep. 63:1979;255-263.
33. Omura G A, Brady M F, Homesley H D, Yordan E, Major F J, Buchsbaum H J, Park R C. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience. J Clin Oncol. 9:1991;1138-1150.
34. Malkasian G D Jr., Melton L Jd, O'Brien P C, Greene M H. Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. Am J Obstet Gynecol. 149:1984;274-284.
35. Silverberg S G. Prognostic significance of pathologic features of ovarian carcinoma. Curr Top Pathol. 78:1989;85-109.
36. Iggo R, Gatter K, Bartek J, Lane D, Harris A. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet. 335:1990;675-679.
37. DiCioccio R A, Werness B A, Peng R, Allen H J, Piver M S. Correlation of TP53 mutations and p53 expression in ovarian tumors. Cancer Genet Cytogenet. 105:1998;93-102.
38. Auer G, Einhorn N, Nilsson B, Silfversward C, Sjovall K. Biological malignancy grading in early-stage ovarian carcinoma. Acta Oncol. 35:1996;93-98.
39. Anttila M A, Kosma V M, Hongxiu J, Puolakka J, Juhola M, Saarikoski S, Syrjanen K. p21/WAF1 expression as related to p53, cell proliferation and prognosis of ovarian cancer. Br J Cancer. 79:1999;11-12.
40. Hansen C, Scudder S A, Walls J E, Costa M J. Immunohistochemical markers of cell cycle control applied to ovarian epithelial neoplasms: p21WAF1/CIP1 predicts survival. Modern Pathol. 11:1998;104A.